Table 2.

TERT promoter mutation status in 86 primary melanomas, 72 nevi, and 40 diagnostically uncertain melanocytic proliferations

TERT promoter mutation*	Primary Melanomas (n=86)	Nevi (n=72)	Uncertain (n=40)
	Number (%)	Number (%)	Number (%)
Hotspot mutations creating ETS/TCF sites†	n=67 (77.9%)	n=1 (1.4%)	n=2 (5.0%)
-124C>T‡	29 (33.7)	1 (1.4)	1 (2.5)
-124_125CC>TT	1 (1.2)
-138_139CC>TT	4 (4.7)
-146C>T§	33 (38.4)		1 (2.5)
Less common mutations creating ETS/TCF sites¶	n=4 (4.7%)		n=1 (2.5%)
-103C>T||	1 (1.2)
-105_106CC>TT	1 (1.2)
-148C>T**	2 (2.3)
-156C>T††			1 (2.5)
Mutations not creating an ETS/TCF site	n=2 (2.3%)	n=7 (9.7%)	n=2 (5.0%)
-85C>T;-154C>T			1 (2.5)
-106C>T;-117C>T;-149C>T		1 (1.4)
-107C>T	1 (1.2)
-116C>T;-179C>T		1 (1.4)
-125C>T		1 (1.4)
-149C>T		2 (2.8)
-149C>T;-127C>T		1 (1.4)
-149C>T;-160C>T			1 (2.5)
-151C>T	1 (1.2)
-161C>T		1 (1.4)
No mutations	13 (15.2)	64 (88.9)	35 (87.5)

^*Bolded mutations create de novo ETS/TCF binding sites.

^†Mutations create confirmed functional ETS/TCF binding sites.

^‡Six melanomas with -124C>T mutations had additional mutations: -124C>T;-101C>T (n=2), -124C>T;-103C>T (n=1), -124C>T;-126C>T (n=1), -124C>T;-131C>T;-166C>T (n=1) and -124C>T;-148C>T (n=1).

^§Twelve melanoma with -146C>T mutations had additional mutations: -146C>T;-107C>T;-117C>T (n=1), -146C>T;-149C>T;-153G>A (n=1), -146C>T;-165C>G (n=1), -146C>T;-116C>T (n=1), -146C>T;-125C>T (n=2), -146C>T;-126C>T;-195C>A (n=1), -146C>T;-127C>T (n=1), -146C>T;-149C>T (n=1), -146C>T;-150C>T (n-1), -146C>T;-150C>T;-166C>T (n=1) and -146C>T;-101C>T;-165C>T (n=1).

^¶Mutations create ETS/TCF sites but less common and not confirmed to be functional.

^||The melanoma with the -103C>T mutation also had a -160C>T mutation.

^**One of the melanomas with a -148C>T mutation also had the following mutations: -161C>T;-175C>T;-187C>T;-242C>T

^††The uncertain sample with the -156C>T mutation also had a -149C>T mutation.